Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Quest Diagnostics sells ibrutinib royalty rights to Royalty Pharma for $485mm in cash

Executive Summary

Quest Diagnostics Inc. has sold its royalty interest in the cancer candidate ibrutinib to Royalty Pharma for $485mm in cash. Ibrutinib is in Phase III for leukemia and lymphoma through a partnership between Pharmacyclics and J&J's Janssen Biotech. (Pharmacyclics owed Celera Corp. single-digit royalties on the project. Quest bought Celera in 2011, and thus gained the royalty rights to the compound.) Quest doesn't see ibrutinib as a core asset, and in line with other recent divestitures (the sale of the POC testing business HemoCue to Radiometer earlier this year and the OralDNA dental diagnostics company to Access Genetics last year), decided to sell the royalty interest so it can continue to focus more on its main diagnostics businesses. From the Celera purchase, Quest still holds onto royalty rights for other compounds, but it has yet to see any of that money.
Deal Industry
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Royalty Sale

Related Companies

Advertisement
UsernamePublicRestriction

Register